The update contains no material new information; the stock is unlikely to react significantly. Focus on the Q2 earnings release on August 4, 2026 for actual financial results and any guidance changes.
Price Chart
Executive Summary
Pediatrix Medical Group issued a Q2 2026 business update confirming stable payor mix and no adverse reimbursement trends, while reaffirming full-year 2026 Adjusted EBITDA guidance of $280M-$300M. No actual Q2 financial results were reported; the update is a routine FD disclosure ahead of the August 4 earnings call.
Key Facts
- Payor mix for Q2 2026 remained stable and unchanged relative to recent historical trends and internal expectations.
- Company has not experienced unfavorable payor mix shifts reported elsewhere in the healthcare sector.
- Full year 2026 Adjusted EBITDA guidance reaffirmed at $280M to $300M.
- Q2 2026 earnings conference call scheduled for August 4, 2026.
Financial Impact
No new financial data provided; guidance unchanged at $280M-$300M Adjusted EBITDA.
Risk Factors
- Potential adverse payor mix shifts could emerge later in the year.
- Macroeconomic or regulatory changes (e.g., Medicaid, surprise billing) could impact reimbursement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-304033 |
| Document: md-20260715.htm | 0001193125-26-304033 |
| Document: 0001193125-26-304033-index-headers.html | 0001193125-26-304033 |
| Document: 0001193125-26-304033-index.html | 0001193125-26-304033 |
| Document: 0001193125-26-304033.txt | 0001193125-26-304033 |
| 8-K Data (Synthetic) | 0001193125-26-304033 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 12w ago | 8-K | $24.71 $26.47 | ▲ +7.12% | ▲ +8.36% | $28.84 (+16.71%) |
Jul 24, 2026 13w ago | 8-K | $26.14 $26.60 | ▲ +1.76% | ▼ −1.54% | $28.84 (+10.33%) |
Jul 15, 2026 14w ago | 8-K | $25.88 $26.50 | ▲ +2.40% | ▲ +0.05% | $28.84 (+11.44%) |
Apr 17, 2026 27w ago | DEFA14A | $23.19 $22.64 | ▼ −2.37% | ▼ −6.57% | $28.84 (+24.36%) |
Mar 27, 2026 30w ago | DEFA14A | $20.50 $23.39 | ▲ +14.10% | ▲ +1.36% | $28.84 (+40.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers